Structures available for Coagulation Factor XI
All structural analysis presented within this database uses the
6I58
structure as reference, taken from the Protein Data Bank.
The FXI structure consists of the Apple 1, Apple 2, Apple 3, Apple 4 and Serine Protease domains.
Experimental Structures available for Human Coagulation Factor XI
PDB |
Method |
Description |
Resolution |
Chain |
Position |
PDBsum |
|---|---|---|---|---|---|---|
| 1XX9 | X-ray | Crystal Structure of the FXIa Catalytic Domain in Complex with EcotinM84R. | 2.2 | A/B | 388-625 | >> |
| 1XXD | X-ray | Crystal Structure of the FXIa Catalytic Domain in Complex with mutated Ecotin. | 2.9 | A/B | 388-625 | >> |
| 1XXF | X-ray | Crystal Structure of the FXIa Catalytic Domain in Complex with Ecotin Mutant (EcotinP). | 2.6 | A/B | 388-624 | >> |
| 1ZHM | X-ray | Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Benzamidine (S434A-T475A-K437 Mutant). | 1.9 | A | 388-624 | >> |
| 1ZHP | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S434A-T475A-K505 Mutant). | 2.7 | A | 388-624 | >> |
| 1ZHR | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S434A-T475A-C482S-K437A Mutant). | 1.7 | A | 388-625 | >> |
| 1ZJD | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Kunitz Protease Inhibitor Domain of Protease Nexin II. | 2.6 | A | 388-624 | >> |
| 1ZLR | X-ray | Factor XI catalytic domain complexed with 2-guanidino-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl nicotinate. | 2.5 | A | 388-624 | >> |
| 1ZMJ | X-ray | Crystal Structure of the Catalytic Domain of Factor XI in complex with 4-(guanidinomethyl)-phenylboronic acid. | 2 | A | 388-624 | >> |
| 1ZML | X-ray | Crystal Structure of the Catalytic Domain of Factor XI in complex with (R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenethyl)guanidine. | 2.2 | A | 388-624 | >> |
| 1ZMN | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with (R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenyl)guanidine. | 2.0 | A | 388-624 | >> |
| 1ZOM | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with a peptidomimetic Inhibitor. | 2.2 | A | 388-624 | >> |
| 1ZPB | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 4-Methyl-pentanoic acid {1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-methyl-propyl}-amide. | 2.1 | A | 388-624 | >> |
| 1ZPC | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-[2-(3-Chloro-phenyl)-2-hydroxy-acetylamino]-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-3-methyl-butyramide. | 2.6 | A | 388-624 | >> |
| 1ZPZ | X-ray | Factor XI catalytic domain complexed with N-((R)-1-(4-bromophenyl)ethyl)urea-Asn-Val-Arg-alpha-ketothiazole. | 2.5 | A | 388-624 | >> |
| 1ZRK | X-ray | Factor XI complexed with 3-hydroxypropyl 3-(7-amidinonaphthalene-1-carboxamido)benzenesulfonate. | 2.3 | A | 388-624 | >> |
| 1ZSJ | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with N-(7-Carbamimidoyl-naphthalen-1-yl)-3-hydroxy-2-methyl-benzamide. | 1.9 | A | 388-625 | >> |
| 1ZSK | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 6-Carbamimidoyl-4-(3-hydroxy-2-methyl-benzoylamino)-naphthalene-2-carboxylic acid methyl ester. | 1.9 | A | 388-625 | >> |
| 1ZSL | X-ray | Factor XI complexed with a pyrimidinone inhibitor. | 2.0 | A | 388-624 | >> |
| 1ZTJ | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Benzylamino-2-methylsulfanyl-6-oxo-6H-pyrimidin-1-yl)-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-acetamide. | 2.0 | A | 388-624 | >> |
| 1ZTK | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Amino-6-oxo-2-m-tolyl-6H-pyrimidin-1-yl)-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-acetamide. | 2.5 | A | 388-624 | >> |
| 1ZTL | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with N-[4-Guanidino-1-(thiazole-2-carbonyl)-butyl]-2-{6-oxo-5-[(quinolin-8-ylmethyl)-amino]-2-m-tolyl-6H-pyrimidin-1-yl}-acetamide. | 2.6 | A | 388-624 | >> |
| 2F83 | X-ray | Crystal structure at 2.9 Angstroms resolution of human plasma coagulation factor XI zymogen. | 2.8 | A | 20-622 | >> |
| 2FDA | X-ray | Crystal Structure of the Catalytic Domain of Human Coagulation Factor XIa in Complex with alpha-Ketothiazole Arginine Derived Ligand. | 2 | A | 388-624 | >> |
| 2J8J | NMR | Solution Structure of the A4 Domain of Blood Coagulation Factor XI. | - | A/B | 290-379 | >> |
| 2J8L | NMR | FXI Apple 4 domain loop-out conformation. | - | A/B | 290-379 | >> |
| 3BG8 | X-ray | Crystal structure of Factor XIa in complex with Clavatadine A. | 1.6 | A | 388-625 | >> |
| 3SOR | X-ray | Factor XIa in complex with a clorophenyl-tetrazole inhibitor. | 1.8 | A | 388-623 | >> |
| 3SOS | X-ray | Benzothiazinone inhibitor in complex with FXIa. | 2.5 | A | 388-623 | >> |
| 4CR5 | X-ray | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design. | 2.0 | A | 388-625 | >> |
| 4CR9 | X-ray | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design. | 1.7 | A | 388-625 | >> |
| 4CRA | X-ray | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design. | 1.8 | A | 388-625 | >> |
| 4CRB | X-ray | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design. | 1.8 | A | 388-625 | >> |
| 4CRC | X-ray | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design. | 1.6 | A | 388-624 | >> |
| 4CRD | X-ray | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design. | 2.1 | A | 388-623 | >> |
| 4CRE | X-ray | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design. | 1.7 | A | 388-625 | >> |
| 4CRF | X-ray | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design. | 2.3 | A | 388-625 | >> |
| 4CRG | X-ray | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design. | 1.2 | A | 388-624 | >> |
| 4D76 | X-ray | Human FXIa in complex with small molecule inhibitors. | 1.7 | A | 388-623 | >> |
| 4D7F | X-ray | Human FXIa in complex with small molecule inhibitors. | 1.6 | A | 388-623 | >> |
| 4D7G | X-ray | Human FXIa in complex with small molecule inhibitors. | 2.3 | A | 388-623 | >> |
| 4NA7 | X-ray | Factor XIA in complex with the inhibitor 3'-[(2S,4R)-6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydroquinolin-2-yl]-4-carbamoyl-5'-[(3-methylbutanoyl)amino]biphenyl-2-carboxylic acid. | 2.8 | A | 388-625 | >> |
| 4NA8 | X-ray | Factor XIa in complex with the inhibitor 5-aminocarbonyl-2-[3-[(2s,4r)-6-carbamimidoyl-4-methyl-4-phenyl-2,3-dihydro-1h-quinolin-2-yl]phenyl]benzoic acid. | 2.3 | A | 388-625 | >> |
| 4TY6 | X-ray | Factor XIa in complex with the inhibitor 4-{2-[(1S)-1-({[trans-4-(aminomethyl)cyclohexyl]carbonyl}amino)-2-phenylethyl]-1H-imidazol-4-yl}benzamide. | 1.8 | A | 388-625 | >> |
| 4TY7 | X-ray | Factor XIa in complex with the inhibitor (2S)-6-amino-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-2-ethylhexanamide. | 2.0 | A | 388-625 | >> |
| 4WXI | X-ray | Factor XIa in complex with the inhibitor trans-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)pyridin-2-yl]-2-phenylethyl}-4-(aminomethyl)cyclohexanecarboxamide. | 2.6 | A | 388-625 | >> |
| 4X6M | X-ray | Factor XIa in complex with the inhibitor 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[2-(aminomethyl)-5-chlorobenzyl]urea. | 2.4 | A | 388-625 | >> |
| 4X6N | X-ray | Factor XIa in complex with the inhibitor 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]urea. | 2.1 | A | 388-625 | >> |
| 4X6O | X-ray | Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]propanoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate. | 2.1 | A | 388-625 | >> |
| 4X6P | X-ray | Factor XIa (PICHIA PASTORIS; C500S [C122S]) in complex with the inhibitor (2E)-N-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-1H-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enamide. | 1.9 | A/B | 388-623 | >> |
| 4Y8X | X-ray | Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate. | 1.9 | A | 388-625 | >> |
| 4Y8Y | X-ray | Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-3-(morpholin-4-yl)-3-oxopropyl]-1H-imidazol-5-yl}phenyl)carbamate. | 2.6 | A | 388-625 | >> |
| 4Y8Z | X-ray | Factor XIa in complex with the inhibitor (2E)-N-[(1S)-1-[5-chloro-4-(4-hydroxy-2-oxo-1,2-dihydroquinolin-6-yl)-1H-imidazol-2-yl]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enamide. | 2.2 | A | 388-625 | >> |
| 5E2O | X-ray | Factor XIa in complex with the inhibitor 4-[(N-{(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}-L-phenylalanyl)amino]benzoic acid. | 2.0 | A | 388-625 | >> |
| 5E2P | X-ray | Factor XIa in complex with the inhibitor N-[(1S)-1-benzyl-2-[2-[5-chloro-2-(tetrazol-1-yl)phenyl]ethylamino]-2-oxo-ethyl]-4-hydroxy-2-oxo-1H-quinoline-6-carboxamide. | 2.1 | A | 388-625 | >> |
| 5EOD | X-ray | Human Plasma Coagulation FXI with peptide LP2. | 3.1 | A | 20-623 | >> |
| 5EOK | X-ray | Human Plasma Coagulation Factor XI in complex with peptide P39. | 2.8 | A | 20-623 | >> |
| 5EXL | X-ray | Factor XIa in complex with the inhibitor 4-(aminomethyl)-~{N}-[(1~{S})-1-[4-(3-oxidanyl-1~{H}-indazol-5-yl)pyridin-2-yl]-2-phenyl-ethyl]cyclohexane-1-carboxamide. | 2.3 | A | 388-625 | >> |
| 5EXM | X-ray | Factor XIa in complex with the inhibitor methyl ~{N}-[4-[2-[(1~{S})-1-[[4-(aminomethyl)cyclohexyl]carbonylamino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate. | 2.0 | A | 388-625 | >> |
| 5EXN | X-ray | Factor XIa (C500S [C122S]) in complex with the inhibitor methyl ~{N}-[4-[2-[(1~{S})-1-[[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]amino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate. | 1.4 | A | 388-624 | >> |
| 5I25 | X-ray | Human recombinant coagulation FXI in complex with a peptide derived from human high molecular weight kininogen (HKP). | 2.8 | A | 19-623 | >> |
| 5Q0D | X-ray | Factor XIa in complex with the inhibitor methyl [(7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-oxo-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecin-14-yl]carbamate. | 2.1 | A | 388-625 | >> |
| 5Q0E | X-ray | Factor XIa in complex with the inhibitor methyl [(4S,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-4-methyl-2-oxo-1,3,4,5,6,7,8,10-octahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate. | 2.1 | A | 388-625 | >> |
| 5Q0F | X-ray | Factor XIa in complex with the inhibitor methyl [(4R,5E,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-4-methyl-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate. | 2.1 | A | 388-625 | >> |
| 5Q0G | X-ray | Factor XIa in complex with the inhibitor methyl [(3R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-3-ethyl-2-oxo-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecin-14-yl]carbamate. | 2.6 | A | 388-625 | >> |
| 5Q0H | X-ray | Factor XIa in complex with the inhibitor methyl [(4R,5E,8S)-11-chloro-8-[(2,6-difluoro-4-methylbenzene-1-carbonyl)amino]-4-methyl-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate. | 2.5 | A | 388-625 | >> |
| 5QCK | X-ray | Factor XIa in complex with the inhibitor 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3-phenyl-pyrrolidin-2-yl]carbonylamino]benzoic acid. | 2.6 | A | 388-625 | >> |
| 5QCL | X-ray | Factor XIa in complex with the inhibitor 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid. | 2.1 | A | 388-625 | >> |
| 5QCM | X-ray | Factor XIa in complex with the inhibitor methyl ~{N}-[4-[[(1~{S})-2-[(~{E})-3-[3-chloranyl-2-fluoranyl-6-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]phenyl]carbamate. | 2.2 | A | 388-625 | >> |
| 5QCN | X-ray | Factor XIa in complex with the inhibitor 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-5-[(3~{S})-3-ethoxycarbonylpiperidin-1-yl]carbonyl-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid. | 2.3 | A | 388-625 | >> |
| 5QQO | X-ray | Factor XIa in complex with the inhibitor methyl [(5E,8S)-8-[(6R)-6-(3-chlorophenyl)-2-oxo-1,3-oxazinan-3-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate. | 2.0 | A | 388-625 | >> |
| 5QQP | X-ray | Factor XIa in complex with the inhibitor methyl [(5E,8S)-8-[(4S)-4-(3-chlorophenyl)-2-oxopiperidin-1-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate. | 2.0 | A | 388-625 | >> |
| 5QTT | X-ray | Factor XIa in complex with the inhibitor methyl [(3R,7S)-7-{[5-amino-1-(3-chloro-2-fluorophenyl)-1H-pyrazole-4-carbonyl]amino}-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecin-15-yl]carbamate. | 2.2 | A | 388-625 | >> |
| 5QTU | X-ray | Factor XIa in complex with the inhibitor methyl [(3R,7S)-7-{[1-(3-chloro-2-fluorophenyl)-5-methyl-1H-imidazole-4-carbonyl]amino}-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecin-15-yl]carbamate. | 2.5 | A | 388-625 | >> |
| 5QTV | X-ray | Factor XIa in complex with the inhibitor methyl [(2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-(trifluoromethyl)-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecin-14-yl]carbamate. | 2.2 | A | 388-625 | >> |
| 5QTW | X-ray | Factor XIa in complex with the inhibitor methyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecine-2-carboxylate. | 2.1 | A | 388-625 | >> |
| 5QTX | X-ray | Factor XIa in complex with the inhibitor ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecine-2-carboxylate. | 2.0 | A | 388-625 | >> |
| 5QTY | X-ray | Factor XIa in complex with the inhibitor ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-15-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecine-2-carboxylate. | 1.8 | A | 388-625 | >> |
| 5TKS | X-ray | Factor XIa in complex with the inhibitor ((15S)-18-Chloro-15-(((2E)-3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl-2-propenoyl)mino)-17, 19-diazatricyclo[14.2.1.0~2,7~]nonadeca-1(18),2,4,6,16(19)-pentaen-5-yl)carbamate. | 1.5 | A | 388-625 | >> |
| 5TKT | X-ray | Factor XIa in complex with the inhibitor methyl ((12E,15S)-15-(((2E)-3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)-2-propenoyl)amino)-9-oxo-8,17,19-triazatricyclo[14.2.1.0~2,7~]nonadeca-1(18),2,4,6,12,16(19)-hexaen-5-yl)carbamate. | 2.1 | A | 388-625 | >> |
| 5TKU | X-ray | Factor XIa in complex with the inhibtor methyl ((15S)-15-(((2e)-3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)-2-propenoyl)amino)-9-oxo-8,17,19-triazatricyclo[14.2.1.0~2,7~]nonadeca-1(18),2,4,6,16(19)-pentaen-5-yl)carbamate. | 2.1 | A | 388-625 | >> |
| 5WB6 | X-ray | Factor XIa in complex with the inhibitor methyl [(11S)-11-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-6-fluoro-2-oxo-1,3,4,10,11,13-hexahydro-2H-5,9:15,12-di(azeno)-1,13-benzodiazacycloheptadecin-18-yl]carbamate. | 2.3 | A | 388-625 | >> |
| 6AOD | X-ray | FXIa antibody complex. | 1.8 | C | 388-623 | >> |
| 6C0S | X-ray | Factor XIA in complex with the inhibitor methyl (4-{6-[(1S)-2-[(3R)-1-acetylpiperidin-3-yl]-1-({(2E)-3-[5-chloro-2- (1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)ethyl]-3-chloropyridazin-4-yl}phenyl) carbamate. | 2.3 | A | 388-625 | >> |
| 6HHC | X-ray | Allosteric Inhibition as a new mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated form of Coagulation Factor XI. | 2.7 | A | 388-623 | >> |
| 6I58 | X-ray | Allosteric activation of human prekallikrein by apple domain disc rotation. | 2.6 | A | 20-623 | >> |
| 6R8X | X-ray | Coagulation Factor XI catalytic domain in complex with FAB-portion of MAA868. | 2.0 | A | 392-623 | >> |
| 6TS4 | X-ray | Coagulation factor XI protease domain in complex with active site inhibitor. | 1.1 | A | 388-623 | >> |
| 6TS5 | X-ray | Coagulation factor XI protease domain in complex with active site inhibitor. | 1.2 | A | 388-623 | >> |
| 6TS6 | X-ray | Coagulation factor XI protease domain in complex with active site inhibitor. | 1.3 | A | 388-623 | >> |
| 6TS7 | X-ray | Coagulation factor XI protease domain in complex with active site inhibitor. | 2.6 | A | 388-623 | >> |
| 6TWB | X-ray | Crystal Structure of the Catalytic Domain of Coagulation Factor XIa in Complex with Double Bridged Peptide F19. | 2.9 | A/H | 388-625 | >> |
| 6TWC | X-ray | Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Double Bridged Peptide F21. | 2.8 | A | 388-625 | >> |
| 6USY | X-ray | Coagulation Factor XI catalytic domain (C123S) in complex with NVP-XIV936. | 1.2 | A | 388-623 | >> |
| 6VLU | X-ray | Factor XIa in complex with compound 7. | 1.6 | A | 388-623 | >> |
| 6VLV | X-ray | Factor XIa in complex with compound 11. | 1.7 | A | 388-623 | >> |
| 6W50 | X-ray | Factor XIa in complex with the inhibitor methyl ((10R,14S)-14-(4-(3-chloro-2,6-difluorophenyl)-6-oxo-3,6-dihydro-1(2H)-pyridinyl)-10-methyl-9-oxo-8,16-diazatricyclo[13.3.1.0~2,7~]nonadeca-1(19),2,4,6,15,17-hexaen-5-yl)carbamate. | 1.9 | A | 388-625 | >> |